3347.HK
TIGERMED
HK$30.94
+2.72%
2026-05-29
About TIGERMED
Hangzhou Tigermed Consulting Co., Ltd, together with its subsidiaries, provides contract research organization services in the People's Republic of China and internationally. The company offers clinical trial operation services, such as clinical pharmacology, registration and regulatory affairs, scientific affairs, medical translation, pharmacovigilance, real-world research, third-party auditing and training, etc. for innovative drugs, generic drugs, and medical devices, as well as supporting services directly related to clinical trials, including clinical operation, clinical trials, and clinical trials management. It also provides clinical trial related and laboratory services in the drug development process comprising data management and statistical analysis, clinical trial site management, subject recruitment, medical imaging, and laboratory services. In addition, the company offers preclinical development services, including medicinal chemistry, compound screening, DMPK, safety and toxicology, bioanalytical, and formulation research and development services; and clinical development services, such as medical writing, clinical monitoring, regulatory affairs, data management and statistical analysis, decentralized clinical trials, clinical development strategy, site management, medical device/in vitro diagnostics, multi-region clinical trial, and vaccine clinical trial services. Further, it provides medical imaging, pharmacovigilance, medical translation, quality assurance, GMP and medical device consulting, central laboratories, functional services, recruitment management, EDC cloud-based system, and remote follow-up center services; and post-marketing clinical research solutions, such as site identification and selection, central monitoring, project team management, vendor management, and SAS project management services. Hangzhou Tigermed Consulting Co., Ltd was incorporated in 2004 and is headquartered in Hangzhou, the People's Republic of China.
Key Fundamentals
P/E Ratio
36.36
Forward P/E
20.32
EPS (TTM)
HK$1.05
ROE
4.2%
Revenue Growth (YoY)
15.2%
Profit Margin
10.9%
Debt/Equity
7.01
Dividend Yield
0.9%
Price/Book
1.36
Beta
0.62
Market Cap
HK$32.87B
Avg Volume (10D)
1.9M
Recent Breakout Signals
No recent breakout signals detected for 3347.HK.
Recent Price Range (60 Days)
60D High
HK$46.90
60D Low
HK$29.64
Avg Volume
1.9M
Latest Close
HK$30.94
Get breakout alerts for 3347.HK
Sign up for Breakout Scanner to receive daily notifications when 3347.HK triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial.
TIGERMED (3347.HK) is listed on the Hong Kong Exchanges (HKEX). Breakout Scanner monitors 3347.HK daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. 3347.HK operates in the Healthcare sector within the Diagnostics & Research industry. Data is provided for informational purposes only and does not constitute financial advice.